Clinical trials: Non-resectable Disease
Sarcoma, Soft Tissue Sarcoma
Gemcitabine Plus Ascorbate for Sarcoma in Adults
This study will enroll patients who have a diagnosis of locally advanced, unresectable or metastatic soft tissue or bone sarcoma (except gastrointestinal stromal tumors and Kaposi's sarcoma) from any site.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor
- Trial name
- NCT03468075
- Testing
- Ascorbate, Gemcitabine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mohammed Milhem, MBBS
Non Small Cell Lung Cancer
Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer
This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant PD-1 antibody plus chemotherapy followed by surgery in resectable stage IIIA-N2 non-small cell lung cancer.
- Trial name
- NCT04422392
- Testing
- Carboplatin, Pemetrexed or Nab-paclitaxel, PD-1 antibody
- Where
- 8 sites in China
- Volunteers
- 93 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Metastatic Pancreatic Cancer
Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer
This research study uses radiation or a gene therapy agent, TNFerade in addition to a dendritic cell vaccine in patients with locally advanced or low volume metastatic pancreatic cancer.
- Trial name
- NCT00868114
- Testing
- KLH-pulsed autologous dendritic cell vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Leo W. Jenkins Cancer Center
Gastrointestinal Stromal Tumors
Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
KIT exon 9 mutants had poorer survival compared with KIT exon 11 mutants when they were treated with the same dose of imatinib, 400 mg per day, and that patients with KIT exon 9 mutation had better progression-free survival with…
- Trial name
- NCT01541709
- Testing
- imatinib
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Asan Medical Center
Paranasal Sinus Cancer, Nasal Cavity Tumor
A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
This study is being done to test a new treatment plan for large tumors in the sinus or nasal cavity that will include endoscopic surgery plus chemotherapy and proton-beam radiation therapy.
- Conditions
- Paranasal Sinus Cancer, Nasal Cavity Tumor, Nasal Cavity Adenocarcinoma
- Trial name
- NCT03274414
- Testing
- Cisplatin, Adjuvant Proton Radiotherapy, Endoscopic Resection
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
This phase Ib trial investigates the side effects of durvalumab and tremelimumab after radioembolization (radiation particles against liver tumors) and to see how well they work in treating patients with liver cancer that cannot…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04605731
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma
TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)
The purpose of this protocol is to provide access to Therasphere treatment for patients with liver tumors.
- Trial name
- TheraSphere (NCT00683631)
- Testing
- TheraSphere HUD
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- University of Louisville
Pancreatic Cancer
Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and may make them more sensitive to radiation therapy. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00077519
- Testing
- tipifarnib, radiation therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pancreatic Carcinoma Stage III
FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer
The study is conducted as a monocentric prospective phase II trial. Patients with unresectable stage III locally advanced pancreatic cancer (defined for extended encasement of superior mesenteric artery/celiac axis/hepatic artery…
- Trial name
- FLAP (NCT02351219)
- Testing
- FOLFOXIRI
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Pancreatic Cancer
Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.
This is a study for patients with advanced pancreatic cancer, using the drugs gemcitabine, docetaxel and capecitabine. Gemcitabine is a drug that has been approved by the FDA.
- Trial name
- NCT00159471
- Testing
- capecitabine, gemcitabine, docetaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Southern California
Metastatic Microsatellite Stable Colorectal Carcinoma, Recurrent Colorectal Carcinoma
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
The phase II trial tests whether pembrolizumab and dendritic cell-based treatment works to shrink tumors in patients with colorectal cancer that does not respond to treatment (refractory).
- Conditions
- Metastatic Microsatellite Stable Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT05518032
- Testing
- Biopsy, Pembrolizumab, Therapeutic Autologous Dendritic Cells
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the…
- Trial name
- NCT04137900
- Testing
- TAB004, Toripalimab
- Where
- 24 sites in United States
- Volunteers
- 499 people
- Sponsor
- TopAlliance Biosciences
Adenocarcinoma of Rectum
First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis
The FOLFIRINOX protocol seems a promising protocol as attack treatment of a rectum cancer, with an objective response rate of about 70 %.
- Trial name
- NCT01674309
- Testing
- FOLFORINOX
- Where
- 37 sites in France
- Volunteers
- 65 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Metastatic Malignant Melanoma
A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
This study is designed to assess the safety and efficacy of a combination of ipilimumab and fotemustine in Patients with Unresectable Locally Advanced or Metastatic Malignant Melanoma.
- Trial name
- NIBIT-M1 (NCT01654692)
- Testing
- Ipilimumab and Fotemustine
- Where
- 7 sites in Italy
- Volunteers
- 86 people
- Sponsor
- Italian Network for Tumor Biotherapy
Colorectal Cancer
A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
This is a multicenter, open-label, Phase 1 study of SC-006 given as a single agent and in combination with ABBV-181 in participants with advanced colorectal cancer (CRC), and consists of Part A (single agent SC-006 dose regimen…
- Trial name
- NCT03035279
- Testing
- SC-006, ABBV-181
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- AbbVie
Melanoma
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
The objective of this study is to evaluate the clinical activity of the GSK2132231A immunotherapeutic in patients with MAGE-A3 positive unresectable metastatic melanoma presenting with the predictive gene signature.
- Trial name
- PREDICT (NCT00942162)
- Testing
- Immunotherapeutic GSK2132231A
- Where
- 63 sites in United States, France and 6 more
- Volunteers
- 125 people
- Sponsor
- GlaxoSmithKline
Non Small Cell Lung Cancer (Stage III)
The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study
This study aimed to evaluate the conversion rate to curative-intent treatment in patients with unresectable stage IIIB-IIIC non-small cell lung cancer (NSCLC) following induction therapy with PD-1 blockade combined with…
- Trial name
- NCT06962189
- Testing
- chemoimmunothrapy
- Volunteers
- 39 people
- Sponsor
- Zhejiang University
Carcinoma, Non-Small-Cell Lung
A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer
Phase II study that will evaluate the activity of gemcitabine as intravesical therapy on the marker lesion in superficial bladder carcinoma at intermediate risk.
- Trial name
- NCT00191490
- Testing
- Gemcitabine, docetaxel, cisplatin
- Where
- Italy
- Volunteers
- 162 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer
A phase II, multicenter, randomized trial of 3D Radiotherapy versus 3D Radiotherapy and erlotinib (Tarceva®) in patients with localized-unresectable (IA-IIIB) non-small cell lung cancer non susceptible for chemotherapy treatment…
- Trial name
- NCT00466089
- Testing
- Erlotinib (Tarceva®)
- Where
- 5 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Hospital of Navarra
Melanoma Stage III, Melanoma Stage IV
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for…
- Trial name
- INTACT/MeRCI (NCT06284590)
- Testing
- L19IL2, L19TNF, L19IL2/L19TNF
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 162 people
- Sponsor
- Philogen S.p.A.